Zomedica Corp. (NYSE American: ZOM) shares peaked 32.86% to 0.465 in the AH session after the Veterinary health company (ZOM) announced that Robert Cohen had been appointed president Chief Executive Officer effective January 1, 2021. Mr. Cohen had previously served as the Head of the Company’s Interim Department.
Ms. Cohen brings executive leadership and operations experience from the medical device, pharmaceutical, and biotechnology industries to Zomedica. After spending several years at three billion-dollar medical technology companies, Mr. Cohen founded a series of smaller businesses as CEO. Due to Mr. Cohen’s successful track record of building early-stage corporations and developing medical devices and biotechnology products, the Board of Directors recruited him. He will continue to lead the development and commercialization of the Company’s point-of-care diagnostic platform, TRUFORMA.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
- Two Promising Pet Stocks for Investment as we Head 2021
- 3 Best Gene Therapy Stocks for long-term Investment
Chairman of the Board Jeff Rowe stated, “Over the last six months, we have been thoroughly impressed with Rob’s business skills and the professional leadership skills he has brought to Zomedica at such an important time. We are delighted that Rob has accepted the CEO position as we move close to our most significant milestone. Our TRUFORMA platform development and commercial launch are perfectly aligned with Rob’s medical gadget launch experience. We remain enthusiastic about our near-term launch, our commercialization strategy, and the longer-term potential of Zomedica.”
Robert Cohensaid in a statement, “I am honored to be taking on this pivotal role. It has been a pleasure to get to know the entire Zomedica team since June when I started with the Company, and I can proudly say that I believe we are strongly positioned to capitalize on our market launch.”